Emergency Use Authorization for Remdesivir and Its Potential Implications

Ther Innov Regul Sci. 2021 Mar;55(2):270-271. doi: 10.1007/s43441-020-00212-5. Epub 2020 Sep 3.

Authors

Cassius Iyad Ochoa Chaar¹, Robert Makuch²

Affiliations

¹ Division of Vascular Surgery, Department of Surgery, Yale University School of Medicine, 333 Cedar Street, Boardman 204, New Haven, CT, 06510, USA. cassius.chaar@yale.edu.
² Director of Regulatory Affairs Track, Yale University School of Public Health, New Haven, CT, USA.

No abstract available

MeSH terms

Adenosine Monophosphate / analogs & derivatives*
Adenosine Monophosphate / therapeutic use
Alanine / analogs & derivatives*
Alanine / therapeutic use
Antiviral Agents / therapeutic use
COVID-19*
Humans
SARS-CoV-2

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States